Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting -New preclinical data on lead in vivo programming program, MT-302, demonstrates strong expression and favorable safety in myeloid cells following a single administration […]
Big strides in solving big human health problems! Careers @ Myeloid